Phase 3 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For Parts A and B:
- People who have been diagnosed with relapsing multiple sclerosis (RMS)
- People whose disability level falls within a certain range on a standard MS scoring scale (EDSS score between 0 and 5.5) at the time of screening
- People whose MS symptoms have been stable for at least 30 days before screening, and remain stable between screening and the first day of the trial
For Part C:
- People who have already completed either Part A (up to Week 24) or Part B (up to Week 96) of this same trial
Who may not be able to join:
For Parts A and B:
- People who have, or are suspected to have, another neurological condition that could look similar to MS
- People who have used higher-dose steroid medications (by mouth or injection) within 30 days before their screening MRI scan — note that steroid creams, eye drops, or inhalers are generally allowed (confirm with trial site)
- People who have received high-dose intravenous or under-the-skin immunoglobulin therapy within 2 months before the trial start date
- People who have ever been treated with anti-CD20 therapies or other treatments that target B cells (a type of immune cell)
- People who have ever been treated with alemtuzumab, cladribine, cyclophosphamide, or mitoxantrone (specific MS or immune-suppressing medicines)
For Part B only (additional restrictions related to one of the study medicines):
- People who have ever been treated with fingolimod or similar medicines that work on a specific part of the immune system (S1P1 modulators)
- People who are taking a certain category of heart rhythm medicines (Class Ia anti-arrhythmics) at the time of screening
For Part C:
- People whose lymphocyte count (a measure of certain immune cells in the blood) falls outside a specified range will not be considered eligible to receive the study treatment in Part C (confirm exact range with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-575-8489
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part A: Area Under the Curve From Week 0 to 24 (AUC0-W24) of Ublituximab; Part A: Maximum Observed Concentration (Cmax) of Ublituximab; Part A: Participant B Cell Counts; Part B: Annualized Relapse Rate (ARR); Part C: Annualized Relapse Rate (ARR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.